E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Moderate persistent asthma |
|
E.1.1.1 | Medical condition in easily understood language |
Asthma is a lung disorder that occurs when your breathing tubes become narrowed. This can lead to symptoms such as wheezing, coughing, chest tightness, and shortness of breath. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the long term (24 weeks) efficacy of two doses (2.5 µg and 5 µg) of tiotropium inhalation solution (administered once daily) compared to placebo and to salmeterol (50 µg; administered twice daily) on top of maintenance therapy with inhaled corticosteroid controller medication in patients with moderate persistent asthma. |
|
E.2.2 | Secondary objectives of the trial |
Evaluate the long term (24 weeks) safety of two doses (2.5 µg and 5 µg) of tiotropium inhalation solution (administered once daily) compared to placebo and to salmeterol (50 µg; administered twice daily) on top of maintenance therapy with inhaled corticosteroid controller medication in patients with moderate persistent asthma. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Outpatients of either sex, aged 18-75 years Diagnosis of moderate persistent asthma. Asthma diagnosis made before age of 40. At leaset a 3 month history of asthma. Pre-bronchodilator FEV1 ≥ 60% and ≤ 90% of predicted at Visit 1. Increase in FEV1 of ≥ 12% and ≥ 200 mL 15 min after 400 µg salbutamol (albuterol) at Visit 1. Maintenance treatment with medium dose of inhaled corticosteroids for at least 4 weeks before Visit 1. Symptomatic despite their current maintenance treatment with ICS (ACQ ≥ 1.5). Variation in absolute pre-BD FEV1 values Visit 1 compared to Visit 2 within ± 30%. Never-smokers or ex-smokers (stopped at least one year prior to enrolment + smoking history of less than 10 pack years). |
|
E.4 | Principal exclusion criteria |
Patients with a significant disease other than asthma. Patients with a clinically relevant abnormal screening haematology or blood chemistry if the abnormalitiy defines a significant disease. Patients with a recent history (i.e. six months or less) of myocardial infarction. Patients who have been hospitalised for cardiac failure during the past year. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year. Patients with lung diseases other than asthma (e.g. COPD). Patients with known active tuberculosis. Patients with malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed. Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion no. 1. Patients with significant alcohol or drug abuse within the past two years. Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the 6 weeks prior to Visit 1 (screening). Pregnant or nursing woman. Women of childbearing potential not using a highly effective method of birth control. Patients with any asthma exacerbation or any respiratory tract infection in the four weeks prior to Visit 1 or during the screening period. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The co-primary endpoints are 1. Peak forced expiratory volume in one second (FEV1) response (within 3 hours post dosing) determined at the end of the 24-week treatment period. 2. Trough forced expiratory volume in one second (FEV1) response determined at the end of the 24-week treatment period. Primary endpoint Meta-Analysis (combined data 205.418 and 205.419 trial): 1. The responder as assessed by the Asthma Control Questionnaire (ACQ) determined at the end of the 24-week treatment period on combined data from the two twin trials 205.418 and 205.419. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The end of the 24-week treatment period. |
|
E.5.2 | Secondary end point(s) |
Peak FVC; trough FVC; FEV1 (AUC0-3h); FVC (AUC0-3h);
individual in-clinic FEV1/FVC/PEF measurements; Asthma Quality of Life
Questionnaire (AQLQ (S)); Home assessment: PEF am/pm (last weekly mean of treatment period), use of PRN rescue medication; daytime and nocturnal symptoms; asthma symptom free days, control of asthma (Asthma Control Questionnaire; ACQ) after 24 weeks treatment. In a subset of patients: FEV1 (AUC0-12h), FEV1 (AUC12-24h), FEV1 (AUC0-24h), FVC (AUC0-12h), FVC (AUC12-24h), FVC (AUC0-24h) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The end of the 24-week treatment period. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 26 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Brazil |
China |
Colombia |
Germany |
India |
Japan |
Mexico |
Peru |
Poland |
Romania |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of trial is last visit of last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |